Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(32 sites)
United States
O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama University of California - San Diego Moores Cancer Center, La Jolla, California University of California San Francisco, San Francisco, California UCLA Health - Santa Monica Cancer Care, Santa Monica, California University of Colorado Cancer Center, Aurora, Colorado Yale Cancer Center, New Haven, Connecticut Norwalk Hospital, Norwalk, Connecticut OSF Saint Francis Medical Center, Peoria, Illinois University of Kansas Medical Center, Kansas City, Kansas Henry Ford Cancer - Detroit, Detroit, Michigan Roswell Park Cancer Institute, Buffalo, New York Perlmutter Cancer Center - NYU Langone Health, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Cleveland Clinic, Cleveland, Ohio USOR - Oncology Associates of Oregon, P.C, Eugene, Oregon SCRI Oncology Partners, Nashville, Tennessee Oncology Consultants Texas Medical Center, Houston, Texas USOR - Texas Oncology - (DFW) Waco, Waco, Texas Huntsman Cancer Institute, Salt Lake City, Utah NEXT Oncology, Fairfax, Virginia Fred Hutchinson Cancer Center, Seattle, Washington Northwest Medical Specialties, Tacoma, Washington Australia
Kinghorn Cancer Centre, Darlinghurst, New South Wales Flinders Medical Centre, Bedford Park, South Australia The Queen Elizabeth Hospital, Woodville South, South Australia Peninsula & South Eastern Hematology and Oncology Group (PAS), Frankston, Victoria Peter MacCallum Cancer Centre, Melbourne, Victoria Linear Clinical Research, Nedlands, Western Australia Canada
Juravinski Cancer Centre, Hamilton, Ontario The Princess Margaret Cancer Centre, Toronto, Ontario Jewish General Hospital, Montreal, Quebec Spain
Hospital Universitario Quirónsalud Madrid, Madrid